This process facilitates anti-cancer immunosurveillance, represented by the higher amount of infiltrating mature DCs and effector T cells in the case of NSCLC patients (Stoll et al., 2016) and increased numbers of circulating NK cells and IFN-γ producing CD4+ and CD8+ T cells in AML patients (Fucikova et al., 2016b). The gene discussed is CD4; the disease is cancer.